Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
CONCLUSION: YKL-40 is a promising biomarker for evaluating PM/DM-ILD activity/severity and predicting disease prognosis. Insights into YKL-40 might help elucidate the pathogenesis of PM/DM-ILD.
PMID: 28711881 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Hozumi H, Fujisawa T, Enomoto N, Nakashima R, Enomoto Y, Suzuki Y, Kono M, Karayama M, Furuhashi K, Murakami A, Inui N, Nakamura Y, Mimori T, Suda T Tags: J Rheumatol Source Type: research